

## HOTEL & REGISTRATION INFORMATION

### ACCOMMODATION

Participants requiring hotel accommodation may book directly with the hotels suggested on the EORTC website <http://www.eortc.be/about/hotels.htm>

• **Sodehotel La Woluwe (avenue E. Mounier, 5 - 1200 Brussels)**

Phone +32 2 775 25 24 - Fax +32 2 770 47 80 - Email: [reservation@sodehotel.eu](mailto:reservation@sodehotel.eu)  
Single / Double: 155 Euros / 172 Euros (breakfast included)

• **Hotel Astrid (Place du Samedi, 11 - 1000 Brussels)**

Phone +32 2 219 31 19 - Fax +32 2 219 31 70 - Email: [info@astridhotel.be](mailto:info@astridhotel.be)  
Single / Double: 107 Euros / 130 Euros (breakfast included)

• **Hotel Atlas (Rue du Vieux Marché aux Grains, 30 - 1000 Brussels)**

Phone +32 2 502 60 06 - Fax +32 2 502 69 35 - Email: [sales@atlas.be](mailto:sales@atlas.be)  
Single / Double: 105 Euros / 120 Euros (breakfast included)

### REGISTRATION

**On-line registration will be available at:**

**<http://www.eortc.be/probe>**

As the number of places on this course is limited, participants are encouraged to register as soon as possible.

Registration fees & Payment	Course + Dinner Early registration	Course + Dinner Late registration
Academics & non-profit organizations	100 Euros	150 Euros
Industry representatives	500 Euros	700 Euros
Students	FREE	FREE

Participants are required to organise their own travel arrangements and pay for flights and accommodation. The fee covers organization and administration costs.

**Advanced registration and payment will be required. The deadline for registration is 1st August 2011.**

**For further information, please contact:**

Ms. Irina GHISLAIN, EORTC Quality of Life Department  
Avenue E. Mounier, 83, Bte 11 • 1200 Brussels, Belgium  
Phone: +32 2 774 10 57 • Fax: +32 2 779 45 68  
E-mail: [irina.ghislain@eortc.be](mailto:irina.ghislain@eortc.be)

## INVITED FACULTY

Matti AAPRO, Clinique de Genolier, CH  
Kristin BJORDAL, Norwegian Radium Hospital, NO  
Andrew BOTTOMLEY, EORTC Headquarters, BE  
Corneel COENS, EORTC Headquarters, BE  
Louis DENIS, Oncology Centre Antwerp, BE  
Henning FLECHTNER, Klinikum Magdeburg, DE  
Patricia GARCIA-PRIETO, Patient Representative, BE  
Jan GEISSLER, Patient Representative, DE  
Carolyn GOTAY, University of British Columbia, CA  
Eva GREIMEL, Medical University, Department of Gynecology, AT  
Petra JELIKOVA, EORTC Headquarters, BE  
Colin JOHNSON, University Surgical Unit, Southampton General Hospital, UK  
Michael KOLLER, University of Regensburg, DE  
Dagmara KULIS, EORTC Headquarters, BE  
John MARINGWA, EORTC Headquarters, BE  
Francesca MARTINELLI, EORTC Headquarters, BE  
Marisa MATIAS, MEP, BE  
David McNAMEE, The Lancet, UK  
Carol MOINPOUR, Fred Hutchinson Cancer Research Center, US  
Joana NAMORADO, European Commission, BE  
Sarunas, NARBUTAS, Patient Representative, LT  
David OSOBA, Quality of Life Consulting, CA  
Mira PAVLOVIC, AFSSAPS representative, FR  
Heide PREUSS, Patient Representative, DE  
Chantal QUINTEN, EORTC Headquarters, BE  
Bryce REEVE, NCI, US  
Jolie RINGASH, The Princess Margaret Hospital, CA  
Jeff SLOAN, Mayo Clinic, US  
Martin TAPHOORN, Medisch Centrum Haaglanden-westeynde, NL  
Yasuhiro TORIGOE, Genentech, US  
Galina VELIKOVA, St. James's University Hospital, UK  
Joachim WEIS, Clinic of Tumorbiology University of Freiburg, DE

### AIM OF THE COURSE

This symposium aims to cover a broad range of topics in **HRQOL, Symptom Research and Cancer clinical trials**. It will address recent developments of EORTC tools, as well as other measures for use in clinical trials, but also have a broader focus including discussing international developments and research in oncology. The faculty are international key opinion leaders in their field who will be able to provide a diverse view on HRQOL. Participants will learn aspects of designing, conducting and analyses of HRQOL in clinical trials.

### CME Accreditation

We expect the program of this event to be accredited by ESMO with 15 ESMO-MORA points Category 1 and by the Accreditation Council of Oncology in Europe (ACOE) with 12 European CME credits.

### Free Fellowship Offers

Ten fellowships will be awarded to young academics (under 35 years old), advanced clinical students or those from developing countries for up to 400 Euros each. This will help to cover a part of the costs (e.g. travel, hotel, taxi fares, etc) to attend the symposium.



## 2<sup>nd</sup> EORTC Symposium

# Quality of Life, Symptom Research and Patient Reported Outcomes in Cancer Clinical Trials

Provisional Program



**7<sup>th</sup>-9<sup>th</sup> September 2011**

To be hosted by  
the European Parliament

Brussels - Belgium

### Chairman

Andrew Bottomley, PhD  
EORTC Assistant Director  
Head of EORTC Quality of Life Department

[www.eortc.be/probe](http://www.eortc.be/probe)



**Wednesday 7<sup>th</sup> September 2011**

- 13.00 - 17.00 Quality of Life Workshops**
- Translations Using Patient Views (J. Maringwa, D. Osoba)
  - Clinical Significance (M. Koller, D. Kulis, P. Jelikova, E. Greimel)
  - Patient Experience (Speakers to be confirmed)
  - Item Response Theory (B. Reeve, J. Sloan)

**Thursday 8<sup>th</sup> September 2011**

**Academic and methodological issues  
Session Chairs: A. Bottomley & H. Flechtner**

- 08.00 - 09.00 Registration & welcome coffee**
- 09.00 - 09.10 Introduction (F. Meunier)
  - 09.10 - 09.20 Key Note Address (Ms. Marisa Matias MEP)
  - 09.20 - 09.30 Welcome and aims of the Symposium (A. Bottomley)
  - 09.30 - 10.00 Basics of design and analysis of HRQOL protocols (C. Coens)
  - 10.00 - 10.20 How to make a HRQOL Measure the EORTC way: New Developments (E. Greimel)

**10.20 - 10.40 Coffee break**

**Methodology of trials with HRQOL issues  
Session Chairs: C. Quinten & G. Velikova**

- 10.40 - 11.10 HRQOL in daily practice – Experience with EORTC tools (G. Velikova)
- 11.10 - 11.40 Using HRQOL as a prognostic factor - Fact or fiction (C. Quinten)
- 11.40 - 12.10 Does it make sense to assess HRQOL in brain cancer (M. Taphoorn)
- 12.10 - 12.40 How best to publish PRO and QOL studies in high impact factor oncology journals (D. McNamee)

**12.40 - 13.40 Lunch/Coffee break**

**Understanding optimal analysis of HRQOL data techniques for cancer clinical trials / Session Chair: C. Moinpour**

- 13.40 - 14.05 Complex analysis strategies for longitudinal data (C. Coens)
- 14.05 - 14.30 Cluster Analysis: Can it Add to your Data ? (F. Martinelli)
- 14.30 - 15.00 Fatigue: Can we measure it in cancer clinical trials? (J. Weis)
- 15.00 - 15.30 Multiple Myeloma and Novel Therapies (A. Bottomley)
- 15.30 - 16.00 Health Economics and QOL (P. Kind)

**Debate - Session Chairs: H. Flechtner & C. Gotay**

- 16.00 - 16.30 Genetics and HRQOL - Related or not - Pro (J. Sloan)
- 16.30 - 17.00 Genetics and HRQOL - Related or not - Con (H. Flechtner)

**20.00 GALA DINNER**

**Friday 9<sup>th</sup> September 2011**

**Patients and Regulatory Views of HRQOL  
Session Chair: M. Aapro**

- 08.30 - 08.40 Welcome and plan of the day (M. Aapro)
- 08.40 - 09.10 Why HRQOL is important to patients - Patient and Surgeon Perspective (L. Denis)
- 09.10 - 09.40 Getting Patients Included in Clinical Trials (H. Preuss, S. Narbutas, P. Garcia-Prieto, J. Geissler)
- 09.40 - 10.10 EMEA experience with HRQOL submissions (M. Pavlovic)
- 10.10 - 10.40 What do companies do with the FDA PRO guidance? (Y. Torigoe)
- 10.40 - 11.10 Ethical issues in EU research: enhancing successful applications for EU funding (J. Namorado)

**11.10 - 11.30 Coffee break**

**International Cooperative Groups and HRQOL (Lessons Learned)  
Session Chair: D. Osoba**

- 11.30 - 12.00 NCIC-CTG experience and success in cancer clinical trials (J. Ringash)
- 12.00 - 12.30 EORTC experience and success in cancer clinical trials (A. Bottomley)
- 12.30 - 13.00 Implementing interventions to enhance QOL in cooperative groups: New Developments (C. Gotay)
- 13.00 - 14.00 Lunch**
- 14.00 - 14.30 Radiotherapy and HRQOL in international cancer clinical trials (K. Bjordal)
- 14.30 - 15.00 SWOG experience (C. Moinpour)

**Translations and the Future for HRQOL  
Session Chair: J. Sloan**

- 15.00 - 15.30 Translations and HRQOL: What is the best approach? (M. Koller)
- 15.30 - 16.00 Minimum Clinically Important Change in QOL based on Clinical Anchors (J. Maringwa)
- 16.00 - 16.20 Coffee Break**
- 16.20 - 16.35 Quality of Life in elderly patients (U. Wedding)
- 16.35 - 16.50 Quality of Life Tools for Elderly Patients (C. Johnson)
- 16.50 - 17.20 Looking back to go ahead (D. Osoba)
- 17.20 Goodbye address and symposium evaluation (A. Bottomley)

**REGISTRATION FORM**

<input type="checkbox"/> Prof	<input type="checkbox"/> Dr	<input type="checkbox"/> Ms	<input type="checkbox"/> Mrs	<input type="checkbox"/> Mr
<b>Title</b>	<b>Last Name</b>	<b>First Name</b>		
<b>Institution / Company</b>				
<b>Department</b>				
<b>Address</b>				
<b>Town</b>	<b>PostCode</b>	<b>Country</b>		
<b>Phone</b>	<b>Fax</b>			
<b>E-mail</b>				
<b>Gender</b>	<input type="checkbox"/> Female	<input type="checkbox"/> Male	<b>Age</b>	<b>Nationality</b>
<b>Speciality</b>				
<b>ESMO Member</b>	<input type="checkbox"/> Yes	<input type="checkbox"/> No	<b>ESMO Member ID Code</b>	

Early registration payments should be received before 1st June 2011.  
Late registration payments should be received between 2nd June 2011 and 1st August 2011.  
The final deadline for all payments is 1st August 2011.

Bank transfer: Fortis Banque SA, 14 av. de l'Astronomie, 1210 Brussels, Belgium  
Account No. 210-0510010-36; IBAN BE46 2100 5100 1036; BIC/SWIFT GEBABEBB  
Communication: "Registration Course QOL PROBE 2011 + Name of participant"

**Signature** \_\_\_\_\_ **Date** \_\_\_\_\_